company background image
ASMB

Assembly Biosciences NasdaqGS:ASMB Stock Report

Last Price

US$1.32

Market Cap

US$64.4m

7D

-2.2%

1Y

-43.8%

Updated

25 Nov, 2022

Data

Company Financials +
ASMB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ASMB Stock Overview

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States.

Assembly Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Assembly Biosciences
Historical stock prices
Current Share PriceUS$1.32
52 Week HighUS$2.45
52 Week LowUS$1.20
Beta0.71
1 Month Change-21.43%
3 Month Change-31.61%
1 Year Change-43.83%
3 Year Change-91.86%
5 Year Change-97.26%
Change since IPO-95.81%

Recent News & Updates

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Nov 09
We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Recent updates

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Nov 09
We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Jun 08
We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Jan 11
We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

We're Keeping An Eye On Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Sep 03
We're Keeping An Eye On Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate

Time To Worry? Analysts Just Downgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Outlook

Mar 24
Time To Worry? Analysts Just Downgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Outlook

Assembly Biosciences' (NASDAQ:ASMB) Shareholders Are Down 86% On Their Shares

Feb 05
Assembly Biosciences' (NASDAQ:ASMB) Shareholders Are Down 86% On Their Shares

We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely

Dec 14
We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely

Shareholder Returns

ASMBUS BiotechsUS Market
7D-2.2%0.4%1.3%
1Y-43.8%-14.4%-18.5%

Return vs Industry: ASMB underperformed the US Biotechs industry which returned -13.5% over the past year.

Return vs Market: ASMB underperformed the US Market which returned -20.2% over the past year.

Price Volatility

Is ASMB's price volatile compared to industry and market?
ASMB volatility
ASMB Average Weekly Movement7.7%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: ASMB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: ASMB's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200570John McHutchisonhttps://www.assemblybio.com

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company’s lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV.

Assembly Biosciences, Inc. Fundamentals Summary

How do Assembly Biosciences's earnings and revenue compare to its market cap?
ASMB fundamental statistics
Market CapUS$64.39m
Earnings (TTM)-US$130.95m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ASMB income statement (TTM)
RevenueUS$0
Cost of RevenueUS$2.75m
Gross Profit-US$2.75m
Other ExpensesUS$128.20m
Earnings-US$130.95m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.68
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ASMB perform over the long term?

See historical performance and comparison